Technical Analysis for ASND - Ascendis Pharma A/S

Grade Last Price % Change Price Change
grade B 119.07 -3.37% -4.15
ASND closed down 3.37 percent on Friday, March 22, 2019, on 81 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical ASND trend table...

Date Alert Name Type % Chg
Mar 22 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Mar 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 22 Multiple of Ten Bearish Other 0.00%
Mar 22 Wide Bands Range Expansion 0.00%
Mar 22 Down 3 Days in a Row Weakness 0.00%
Mar 22 Down 4 Days in a Row Weakness 0.00%
Mar 21 MACD Bearish Signal Line Cross Bearish -3.37%
Mar 21 1,2,3 Pullback Bullish Bullish Swing Setup -3.37%
Mar 21 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -3.37%
Mar 21 Wide Bands Range Expansion -3.37%

Older signals for ASND ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone that has completed Phase II clinical trials in adults to treat growth hormone deficiency (GHD) and other indications, as well as in Phase II studies in children for treating GHD; and TransCon Treprostinil for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. The company is also developing TransCon Insulin for the treatment of diabetes; and TransCon Ranibizumab, a compound to support ranibizumab injection. It has strategic collaborations with Sanofi, Genentech, and United Therapeutics Corporation. The company was founded in 2006 and is headquartered in Hellerup, Denmark.
Biotechnology Life Sciences Disease Diabetes Hormones Pulmonary Arterial Hypertension Peptide Hormones Treatment Of Diabetes Breakthrough Therapy Genentech Recombinant Proteins Treprostinil
Is ASND a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 131.755
52 Week Low 53.205
Average Volume 419,175
200-Day Moving Average 71.3379
50-Day Moving Average 87.1774
20-Day Moving Average 111.241
10-Day Moving Average 125.988
Average True Range 5.8189
ADX 43.07
+DI 34.2509
-DI 19.8855
Chandelier Exit (Long, 3 ATRs ) 114.2983
Chandelier Exit (Short, 3 ATRs ) 84.8167
Upper Bollinger Band 156.4037
Lower Bollinger Band 66.0783
Percent B (%b) 0.59
BandWidth 81.19794
MACD Line 12.5244
MACD Signal Line 13.4487
MACD Histogram -0.9243
Fundamentals Value
Market Cap 3.87 Billion
Num Shares 32.5 Million
EPS -3.61
Price-to-Earnings (P/E) Ratio -32.98
Price-to-Sales 288.07
Price-to-Book 6.90
PEG Ratio -0.32
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 130.95
Resistance 3 (R3) 131.35 127.80 128.97
Resistance 2 (R2) 127.80 124.77 127.60 128.31
Resistance 1 (R1) 123.43 122.90 121.66 123.03 127.65
Pivot Point 119.88 119.88 118.99 119.68 119.88
Support 1 (S1) 115.51 116.85 113.73 115.11 110.49
Support 2 (S2) 111.96 114.98 111.75 109.83
Support 3 (S3) 107.59 111.96 109.17
Support 4 (S4) 107.19